Authors reported that patients administered oral THC experienced a “nine-fold greater reduction in opioid consumption” compared to controls.
The transdermal application of plant-derived CBD reduces fascial pain in patients with temporomandibular disorders (TMD aka TMJ), according to clinical data published in the Journal of Clinical Medicine.
Researchers reported: “For the first time, we show a statistically significant negative association between recreational access to cannabis and OTC sleep aid sales.”
Authors found “little support for a causal effect of cannabis use on cognition. This conclusion is consistent with those from previous twin studies, which suggest that cannabis use does not cause a decline in cognitive ability among a normative cannabis using sample.”
Authors reported “an independent negative association between frequent cannabis use and frequent illicit opioid use.” Specifically, subjects who consumed cannabis daily “had about 50 percent lower odds of using illicit opioids every day [as] compared to cannabis non-users.”
Investigators lab-tested 30 CBD products obtained from leading online retailers. Twenty of the thirty products possessed significant deviations in CBD content as compared to what was advertised. Sixteen of the 20 products contained lower percentages of CBD than the amount stated on the product’s label.
“Individuals who report having pain limiting that limits their daily activity see large health improvements. This is the strongest evidence that a group with a high probability of pain medication use sees large benefits from medical marijuana laws.”
On Wednesday, October 23rd, members of the Senate Senate International Narcotics Control Caucus (aka the Drug Caucus) will hold a hearing entitled “Marijuana and America’s Health: Questions and Issues for Policy Makers.”